$MIRM
Mirum Pharmaceuticals, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023006715 Filed on March 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $31.60M $27.91M $77.06M
YoY Change 145.1% 789.29% 302.66%
Cost Of Revenue $4.979M $4.494M $12.37M
YoY Change 105.4% 136.15% 550.24%
Gross Profit $26.62M $23.41M $64.69M
YoY Change 154.29% 1795.71% 275.33%
Gross Profit Margin 84.24% 83.9% 83.94%
Selling, General & Admin $30.22M $26.47M $89.07M
YoY Change 58.08% 39.05% 50.4%
% of Gross Profit 113.52% 113.05% 137.69%
Research & Development $23.55M $31.11M $106.8M
YoY Change -2.24% 11.99% -18.71%
% of Gross Profit 88.46% 132.86% 165.17%
Depreciation & Amortization $1.337M $1.201M $3.238M
YoY Change 290.94% 251.17% 444.2%
% of Gross Profit 5.02% 5.13% 5.01%
Operating Expenses $58.75M $57.57M $208.3M
YoY Change 28.75% 22.99% 8.17%
Operating Profit -$27.15M -$34.16M -$131.2M
YoY Change -17.07% -25.04% -24.33%
Interest Expense -$1.970M -$1.542M -$11.22M
YoY Change -46.83% -68.21% -37.54%
% of Operating Profit
Other Income/Expense, Net -$811.0K -$588.0K $365.0K
YoY Change 426.62% 3358.82% -162.71%
Pretax Income -$29.93M -$36.29M -$142.1M
YoY Change -18.22% -163.05% 69.23%
Income Tax $201.0K $140.0K -$6.406M
% Of Pretax Income
Net Earnings -$30.13M -$36.43M -$135.7M
YoY Change -17.69% -163.31% 61.53%
Net Earnings / Revenue -95.35% -130.55% -176.05%
Basic Earnings Per Share -$0.80 -$4.01
Diluted Earnings Per Share -$0.80 -$0.99 -$4.02
COMMON SHARES
Basic Shares Outstanding 37.95M 36.87M 33.84M
Diluted Shares Outstanding 37.68M 33.98M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $132.1M $151.7M $151.7M
YoY Change -5.6% -3.08% -3.08%
Cash & Equivalents $49.42M $28.00M $28.00M
Short-Term Investments $82.65M $123.7M $123.7M
Other Short-Term Assets $8.987M $8.947M $8.947M
YoY Change 52.12% 69.74% 69.74%
Inventory $6.613M $5.565M $5.565M
Prepaid Expenses
Receivables $24.66M $23.99M $23.99M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $172.3M $190.2M $190.2M
YoY Change 10.99% 14.19% 14.19%
LONG-TERM ASSETS
Property, Plant & Equipment $877.0K $914.0K $2.345M
YoY Change -2.34% -6.83% -8.04%
Goodwill
YoY Change
Intangibles $57.70M $58.95M
YoY Change 212.19% 214.59%
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $1.337M $1.382M $101.4M
YoY Change -34.24% -22.62% -0.4%
Total Long-Term Assets $161.2M $162.7M $162.7M
YoY Change 31.18% 27.04% 27.04%
TOTAL ASSETS
Total Short-Term Assets $172.3M $190.2M $190.2M
Total Long-Term Assets $161.2M $162.7M $162.7M
Total Assets $333.5M $352.9M $352.9M
YoY Change 19.91% 19.77% 19.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.440M $8.690M $8.690M
YoY Change 30.29% -5.19% -5.19%
Accrued Expenses $40.40M $54.02M $54.95M
YoY Change 50.28% 75.82% 74.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.84M $64.73M $64.73M
YoY Change 41.36% 51.96% 51.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $772.0K $4.532M $146.1M
YoY Change 7620.0% 26558.82% 10.84%
Total Long-Term Liabilities $772.0K $4.532M $146.1M
YoY Change 7620.0% 26558.82% 10.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.84M $64.73M $64.73M
Total Long-Term Liabilities $772.0K $4.532M $146.1M
Total Liabilities $192.4M $210.9M $210.9M
YoY Change 13.69% 20.88% 20.88%
SHAREHOLDERS EQUITY
Retained Earnings -$423.0M -$392.8M
YoY Change 43.98% 52.75%
Common Stock $564.0M $535.1M
YoY Change 40.0% 41.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $141.2M $142.0M $142.0M
YoY Change
Total Liabilities & Shareholders Equity $333.5M $352.9M $352.9M
YoY Change 19.91% 19.77% 19.77%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$30.13M -$36.43M -$135.7M
YoY Change -17.69% -163.31% 61.53%
Depreciation, Depletion And Amortization $1.337M $1.201M $3.238M
YoY Change 290.94% 251.17% 444.2%
Cash From Operating Activities -$33.77M -$34.27M -$120.1M
YoY Change -14.86% 3.39% -9.51%
INVESTING ACTIVITIES
Capital Expenditures $41.00K $242.0K $278.0K
YoY Change -101.27% 1058.33%
Acquisitions $0.00
YoY Change
Other Investing Activities $42.06M $27.00M $7.978M
YoY Change 15.22% -78.74% -88.19%
Cash From Investing Activities $42.02M $26.76M $7.700M
YoY Change 15.11% -75.23% -84.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $21.29M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.99M -329.0K 109.1M
YoY Change -28.26% -153.5% 48.49%
NET CHANGE
Cash From Operating Activities -33.77M -34.27M -120.1M
Cash From Investing Activities 42.02M 26.76M 7.700M
Cash From Financing Activities 12.99M -329.0K 109.1M
Net Change In Cash 21.42M -7.841M -3.337M
YoY Change 43.42% -110.39% -68.95%
FREE CASH FLOW
Cash From Operating Activities -$33.77M -$34.27M -$120.1M
Capital Expenditures $41.00K $242.0K $278.0K
Free Cash Flow -$33.82M -$34.51M -$120.4M
YoY Change -14.76% 144.0% -9.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Public Float
EntityPublicFloat
609000000.0
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37950968
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001759425
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesCurrent
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y6M
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38981
CY2022 dei Entity Registrant Name
EntityRegistrantName
Mirum Pharmaceuticals, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1281555
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
950 Tower Lane, Suite 1050
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
667-4085
CY2022 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
MIRM
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Irvine, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28003000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31340000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
123716000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
125201000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23994000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3267000
CY2022Q4 us-gaap Inventory Net
InventoryNet
5565000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1513000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8947000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5271000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
190225000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
166592000
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2021Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
4983000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
914000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
981000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1431000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1569000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
58954000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18740000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1382000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1786000
CY2022Q4 us-gaap Assets
Assets
352906000
CY2021Q4 us-gaap Assets
Assets
294651000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8690000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9166000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54018000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30723000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
931000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
711000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1090000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1996000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64729000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42596000
CY2022Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
140351000
CY2021Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
129923000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1257000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1903000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4532000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17000
CY2022Q4 us-gaap Liabilities
Liabilities
210869000
CY2021Q4 us-gaap Liabilities
Liabilities
174439000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2021Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36956345
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36956345
CY2022Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30705060
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30582596
CY2021Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
122464
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
535074000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
377403000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392824000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257159000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-217000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-35000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
142037000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
120212000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
352906000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294651000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
77062000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19138000
CY2022 mirm Cost Of Sales1
CostOfSales1
12374000
CY2021 mirm Cost Of Sales1
CostOfSales1
1903000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
106842000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
131428000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
89066000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59220000
CY2022 us-gaap Operating Expenses
OperatingExpenses
208282000
CY2021 us-gaap Operating Expenses
OperatingExpenses
192551000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-131220000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-173413000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
3857000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
366000
CY2022 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
15979000
CY2021 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
17590000
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-906000
CY2021 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
732000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
365000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-582000
CY2022 mirm Gain On Sale Of Priority Review Voucher
GainOnSaleOfPriorityReviewVoucher
0
CY2021 mirm Gain On Sale Of Priority Review Voucher
GainOnSaleOfPriorityReviewVoucher
108000000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-142071000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83951000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6406000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-135665000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83988000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.77
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.02
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.77
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33839072
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30321722
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33982493
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30321722
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-135665000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83988000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-194000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-117000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
12000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135847000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84106000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23087000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83988000
CY2021 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-118000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
120212000
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
15585000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27448000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-135665000
CY2022 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-182000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
142037000
CY2022 us-gaap Profit Loss
ProfitLoss
-135665000
CY2021 us-gaap Profit Loss
ProfitLoss
-83988000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
27007000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
23087000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3238000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
595000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
443000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
380000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1703000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
137000
CY2022 mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
15979000
CY2021 mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
17590000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
906000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
-732000
CY2022 mirm Change In Fair Value Of Contingent Liabilities Associated With Acquisition
ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition
899000
CY2021 mirm Change In Fair Value Of Contingent Liabilities Associated With Acquisition
ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition
0
CY2022 mirm Tax Benefit Associated With An Acquisition
TaxBenefitAssociatedWithAnAcquisition
6580000
CY2021 mirm Tax Benefit Associated With An Acquisition
TaxBenefitAssociatedWithAnAcquisition
-0
CY2022 mirm Gain On Sale Of Priority Review Voucher Net
GainOnSaleOfPriorityReviewVoucherNet
0
CY2021 mirm Gain On Sale Of Priority Review Voucher Net
GainOnSaleOfPriorityReviewVoucherNet
108000000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20727000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3676000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4009000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3448000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
495000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
127000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
519000
CY2022 mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
7639000
CY2021 mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
22655000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-711000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-649000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120136000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132758000
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
132322000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
198029000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
140300000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
155600000
CY2022 mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
0
CY2021 mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
2000000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
278000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2022 mirm Proceeds From Sale Of Priority Review Voucher Net
ProceedsFromSaleOfPriorityReviewVoucherNet
0
CY2021 mirm Proceeds From Sale Of Priority Review Voucher Net
ProceedsFromSaleOfPriorityReviewVoucherNet
108000000
CY2022 mirm Additions To Intangible Assets
AdditionsToIntangibleAssets
0
CY2021 mirm Additions To Intangible Assets
AdditionsToIntangibleAssets
-19000000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7700000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48547000
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
86078000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6914000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21289000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7272000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2098000
CY2022 mirm Proceeds From Revenue Interest Liability
ProceedsFromRevenueInterestLiability
0
CY2021 mirm Proceeds From Revenue Interest Liability
ProceedsFromRevenueInterestLiability
64575000
CY2022 mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
-5552000
CY2021 mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
-121000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109087000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73466000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3337000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10746000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131340000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142086000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
128003000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131340000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
911000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
864000
CY2022 mirm Issuance Of Common Stock In Exchange For Acquired Intangible Assets
IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets
15585000
CY2021 mirm Issuance Of Common Stock In Exchange For Acquired Intangible Assets
IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets
0
CY2022 mirm Accrued Milestone Payments Classified As Intangible Assets Net
AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet
15000000
CY2021 mirm Accrued Milestone Payments Classified As Intangible Assets Net
AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet
0
CY2022 mirm Deferred Tax Liability Incurred From Acquired Intangible
DeferredTaxLiabilityIncurredFromAcquiredIntangible
6580000
CY2021 mirm Deferred Tax Liability Incurred From Acquired Intangible
DeferredTaxLiabilityIncurredFromAcquiredIntangible
0
CY2022 mirm Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets
ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets
4600000
CY2021 mirm Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets
ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets
0
CY2022 mirm Indemnification Holdback Liability In Exchange For Acquired Intangible Assets
IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets
831000
CY2021 mirm Indemnification Holdback Liability In Exchange For Acquired Intangible Assets
IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets
0
CY2022 mirm Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
441000
CY2021 mirm Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
71000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
285000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022 mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
163000
CY2021 mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
1018000
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392800000
CY2022Q4 mirm Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
251700000
CY2022Q4 mirm Unrestricted Cash Cash Equivalents And Short And Long Term Investments
UnrestrictedCashCashEquivalentsAndShortAndLongTermInvestments
151700000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.28%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.28%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></p><p style="text-indent:4.28%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s consolidated financial statements as of and for the year ended December 31, 2022 reflect the Company’s estimates of the impact of the geopolitical and macroeconomic environment, including the impact of inflation, higher interest rates, foreign exchange rate fluctuations and the COVID-19 pandemic. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></p>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28003000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31340000
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2021Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
128003000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131340000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
5035000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
33779000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
58954000
CY2021Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
258604000
CY2022 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
CY2022 mirm No Of Customers
NoOfCustomers
1
CY2021 mirm No Of Customers
NoOfCustomers
1
CY2022 mirm Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P3M
CY2022 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2022 us-gaap Advertising Expense
AdvertisingExpense
4000000.0
CY2021 us-gaap Advertising Expense
AdvertisingExpense
9200000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1000000.0
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
700000
CY2022 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
300000
CY2021 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
300000
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
62107000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3153000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
58954000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
260000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18740000
CY2022 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P11Y10M24D
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2900000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
5035000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
5035000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5035000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
5035000
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12Y
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-135665000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-83988000
CY2022 mirm Fair Value Adjustment Of Holdback Indemnification Liability
FairValueAdjustmentOfHoldbackIndemnificationLiability
214000
CY2021 mirm Fair Value Adjustment Of Holdback Indemnification Liability
FairValueAdjustmentOfHoldbackIndemnificationLiability
0
CY2022 mirm Fair Value Adjustment Of Contingent Milestone Liability
FairValueAdjustmentOfContingentMilestoneLiability
700000
CY2021 mirm Fair Value Adjustment Of Contingent Milestone Liability
FairValueAdjustmentOfContingentMilestoneLiability
0
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-136579000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-83988000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33839072
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30321722
CY2022 mirm Weighted Average Holdback Indemnification Shares Issuable
WeightedAverageHoldbackIndemnificationSharesIssuable
19590
CY2021 mirm Weighted Average Holdback Indemnification Shares Issuable
WeightedAverageHoldbackIndemnificationSharesIssuable
0
CY2022 mirm Weighted Average Contingent Shares
WeightedAverageContingentShares
123831
CY2021 mirm Weighted Average Contingent Shares
WeightedAverageContingentShares
0
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33982493
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30321722
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.77
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.02
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.77
CY2022Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
247942000
CY2021Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
258640000
CY2021Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
36000
CY2021Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
258604000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
28420000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
125201000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4983000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8981862
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7086146
CY2021 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
732000
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-906000
CY2022Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
248172000
CY2022Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
230000
CY2022Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
247942000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
24226000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
123716000
CY2021 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
0
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
856000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
5351000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
570000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
214000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
87000
CY2022Q4 us-gaap Inventory Net
InventoryNet
5565000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1513000
CY2022Q4 mirm Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
15000000
CY2021Q4 mirm Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
0
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14660000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9988000
CY2022Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
8319000
CY2021Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
6732000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5372000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2458000
CY2022Q4 mirm Accrued Rebates Payable Current
AccruedRebatesPayableCurrent
4284000
CY2021Q4 mirm Accrued Rebates Payable Current
AccruedRebatesPayableCurrent
265000
CY2022Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
3927000
CY2021Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
4635000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2456000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
345000
CY2022Q4 mirm Accrued Collaboration Liabilities Current
AccruedCollaborationLiabilitiesCurrent
0
CY2021Q4 mirm Accrued Collaboration Liabilities Current
AccruedCollaborationLiabilitiesCurrent
6300000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54018000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30723000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
157000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
37000
CY2020Q4 mirm Revenue Interest Liability
RevenueInterestLiability
47651000
CY2021 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
65000000
CY2021 mirm Interest Expense Accrued
InterestExpenseAccrued
17590000
CY2021 mirm Debt Issuances Costs Capitalized
DebtIssuancesCostsCapitalized
-197000
CY2021 mirm Revenue Interest Payments
RevenueInterestPayments
-121000
CY2021Q4 mirm Revenue Interest Liability
RevenueInterestLiability
129923000
CY2022 mirm Interest Expense Accrued
InterestExpenseAccrued
15979000
CY2022 mirm Revenue Interest Payments
RevenueInterestPayments
-5551000
CY2022Q4 mirm Revenue Interest Liability
RevenueInterestLiability
140351000
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600
CY2022 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease term is approximately four years with an option to extend the term for one five-year term, which at the time was not reasonably assured of exercise and therefore, not included in the lease term.
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q1 mirm Tenant Improvement Allowance
TenantImprovementAllowance
400000
CY2022Q2 us-gaap Area Of Land
AreaOfLand
3500
CY2022Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease commenced in November 2022 and has a term of approximately two and a half years with no option to extend the term.
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
300000
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1400000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1064000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1072000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
242000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2378000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
190000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2188000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2022 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
200000
CY2020Q3 mirm Maximum Amount Of Sale Covered In Shelf Registration Statement
MaximumAmountOfSaleCoveredInShelfRegistrationStatement
300000000.0
CY2022Q4 mirm Common Stock Aggregate Offering Price Remaining
CommonStockAggregateOfferingPriceRemaining
46300000
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11941705
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10286323
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
18000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27007000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23016000
CY2022 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000
CY2021 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
100000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-142661000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-84217000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
590000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
266000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-142071000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83951000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
175000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
37000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-5503000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1078000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6581000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6406000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0740
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0132
CY2022 mirm Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0065
CY2021 mirm Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0170
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.0093
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0002
CY2022 mirm Effective Income Tax Rate Reconciliation Executive Compensation
EffectiveIncomeTaxRateReconciliationExecutiveCompensation
-0.0299
CY2021 mirm Effective Income Tax Rate Reconciliation Executive Compensation
EffectiveIncomeTaxRateReconciliationExecutiveCompensation
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Gilti Percent
EffectiveIncomeTaxRateReconciliationGiltiPercent
0.0143
CY2021 us-gaap Effective Income Tax Rate Reconciliation Gilti Percent
EffectiveIncomeTaxRateReconciliationGiltiPercent
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0496
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0772
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2285
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2841
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0451
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0005
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34522000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31819000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
26747000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
18501000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
23569000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6726000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5815000
CY2022Q4 mirm Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
4733000
CY2021Q4 mirm Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
10277000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
3527000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4027000
CY2022Q4 mirm Deferred Tax Assets Interest Limitation Attributes
DeferredTaxAssetsInterestLimitationAttributes
3127000
CY2021Q4 mirm Deferred Tax Assets Interest Limitation Attributes
DeferredTaxAssetsInterestLimitationAttributes
0
CY2022Q4 mirm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
460000
CY2021Q4 mirm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
543000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
103411000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
70982000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
272000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
319000
CY2022Q4 mirm Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
100000
CY2021Q4 mirm Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
138000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
372000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
457000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
103039000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70525000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
32500000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
23900000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6399000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3933000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2855000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2466000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9254000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6399000
CY2022Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2021Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0

Files In Submission

Name View Source Status
mirm-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-006715-index-headers.html Edgar Link pending
0000950170-23-006715-index.html Edgar Link pending
0000950170-23-006715.txt Edgar Link pending
0000950170-23-006715-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img68857459_0.jpg Edgar Link pending
img68857459_1.jpg Edgar Link pending
mirm-20221231_cal.xml Edgar Link unprocessable
img68857459_2.jpg Edgar Link pending
img68857459_3.jpg Edgar Link pending
img68857459_4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
mirm-20221231.htm Edgar Link pending
mirm-20221231.xsd Edgar Link pending
mirm-ex10_11.htm Edgar Link pending
mirm-ex21_1.htm Edgar Link pending
mirm-ex23_1.htm Edgar Link pending
mirm-ex31_1.htm Edgar Link pending
mirm-ex31_2.htm Edgar Link pending
mirm-ex32_1.htm Edgar Link pending
mirm-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
mirm-20221231_def.xml Edgar Link unprocessable
mirm-20221231_lab.xml Edgar Link unprocessable
mirm-20221231_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending